PS
NVCR icon

Principal Securities’s NovoCure NVCR Stock Holding History

Principal Securities’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$646 – 2782
2025
Q3 		$646 Sell
50
-16
-24% -$214 ﹤0.01% 3489
2025
Q2 		$1.18K Hold
66
– – ﹤0.01% 3298
2025
Q1 		$1.97K Hold
66
– – ﹤0.01% 3044
2024
Q4 		$1.97K Sell
66
-14
-18% -$296 ﹤0.01% 3038
2024
Q3 		$1.25K Sell
80
-6
-7% -$109 ﹤0.01% 3087
2024
Q2 		$1.47K Buy
86
+53
+161% +$932 ﹤0.01% 2985
2024
Q1 		$516 Buy
33
+1
+3% +$15 ﹤0.01% 3137
2023
Q4 		$478 Buy
+32
New +$428 ﹤0.01% 3068

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Principal Securities's NVCR Position: Q4 2025 in Review

Principal Securities sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 50 shares — an estimated $646 sold.

Principal Securities first reported a position in NVCR in Q4 2023 and held it in 8 quarters. The position peaked at $1.97K in Q1 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Principal Securities reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 50 NovoCure shares in Q4 2025, an estimated $646.
  • Principal Securities first reported a position in NovoCure in Q4 2023 and held it in 8 quarters.
  • Principal Securities's NovoCure position peaked at $1.97K in Q1 2025.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.